Compare SCOR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | CRDF |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6M | 86.8M |
| IPO Year | 2007 | 2012 |
| Metric | SCOR | CRDF |
|---|---|---|
| Price | $4.89 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 44.4K | ★ 615.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,549,000.00 | $365,993.00 |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.02 | ★ 49.61 |
| 52 Week Low | $4.60 | $0.76 |
| 52 Week High | $10.18 | $3.31 |
| Indicator | SCOR | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 72.12 |
| Support Level | $4.60 | $1.18 |
| Resistance Level | $7.72 | $1.43 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 42.76 | 93.83 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.